Showing results (171-180 of 205) with videos related to
Sort By:
Pageof 21
Breast (Edinburgh, Scotland)|October 16, 2020
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 studyPeter A Fasching, J Thaddeus Beck, Arlene Chan, et al.The Oncologist|March 22, 2015
In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?Xavier Pivot, Laura Mansi, Loic Chaigneau, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancerJavier Cortés, Pierre Fumoleau, Giulia Valeria Bianchi, et al.Journal of Cachexia, Sarcopenia and Muscle|January 6, 2024
A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patientsJoris Mallard, Elyse Hucteau, Laura Bender, et al.Clinical Breast Cancer|July 9, 2023
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast CancerXavier Pivot, Jean-Philippe Spano, Marc Espie, et al.Nanoscale|February 4, 2025
Spacer engineering in nanoparticle-peptide conjugates boosts targeting specificity for tumor-associated antigensMaría de Los Angeles Ramírez, Jolie Bou-Gharios, Barbara Freis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W Sledge, Masakazu Toi, Patrick Neven, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast CancerPatrick Neven, Stephen R D Johnston, Masakazu Toi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerXavier Pivot, Alexey Manikhas, Bogdan Żurawski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)Stéphane Culine, Alain Lortholary, Jean-Jacques Voigt, et al.Pageof 21